Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
  • Ingenol analogs, pharmaceutical compositions and methods of use thereof
    Patent number: 10583140
    Abstract: The invention relates to compounds of Formula (I), (II), (III) or (IV), salts thereof, pharmaceutical compositions thereof, as well as methods of treating, curing or preventing HIV in subjects.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: March 10, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Vincent Wing-Fai Tai, Jun Tang
  • CHEMICAL COMPOUNDS
    Publication number: 20200071311
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 5, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
  • Modulators of indoleamine 2,3-dioxygenase
    Patent number: 10538495
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: January 21, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Brian Alvin Johns, Wieslaw Mieczyslaw Kazmierski, Martha Alicia De La Rosa, Vicente Samano
  • Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
    Patent number: 10513517
    Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: December 24, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Ian Baxter Campbell, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, Seble Lemma, Simon John Fawcett MacDonald, John Martin Pritchard, Panayiotis Alexandrou Procopiou
  • Nrf2 regulators
    Patent number: 10485806
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 26, 2019
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: Jeffrey K. Kerns, James Francis Callahan, Hongxing Yan, Thomas Daniel Heightman, Jeffrey Charles Boehm, Alison Jo-Anne Woolford
  • Naphthyridines as integrin antagonists
    Patent number: 10487080
    Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and R3 are as defined in the description and claims, or pharmaceutically acceptable salts thereof, having ?v?6 integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an ?v?6 integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 26, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, Seble Lemma, John Martin Pritchard, Panayiotis Alexandrou Procopiou, Steven Leslie Sollis
  • Soluble guanylate cyclase activators and their use
    Patent number: 10472350
    Abstract: The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: November 12, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Nerina Dodic, Anne Marie Jeanne Bouillot
  • Modulators of indoleamine 2,3-dioxygenase
    Patent number: 10472336
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: November 12, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Pek Yoke Chong, Martha Alicia De La Rosa, Hamilton D. Dickson, Wieslaw Mieczyslaw Kazmierski, Vicente Samano, Vincent Wing-Fai Tai
  • Chemical compounds
    Patent number: 10457674
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: October 29, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Transient transfection method for retroviral production
    Patent number: 10450574
    Abstract: The invention relates to bacterial artificial chromosomes (BAC) comprising retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof, wherein each of the retroviral nucleic acid sequences are arranged as individual expression constructs within the BAC. The invention also relates to uses and methods of transient transfection using said BAC.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sabine Johnson, Celeste Pallant, Eirini Vamva, Conrad Vink
  • Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists
    Patent number: 10450312
    Abstract: A compound of formula (I) or a salt thereof wherein R1 represents a hydrogen atom, a methyl group or a ethyl group R2 represents a hydrogen atom or a fluorine atom R3 represents a hydrogen atom, a methyl group or an ethyl group.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Brendan John Fallon, John Martin Pritchard
  • Cyclic di-nucleotides as modulators of STING
    Patent number: 10450341
    Abstract: A compound of formula (1) Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer and as vaccine adjuvants.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Keith Biggadike, Aurelie Cecile Champigny, Diane Mary Coe, Deborah Needham, Daniel Terence Tape
  • Benzimidazole derivatives as bromodomain inhibitors
    Patent number: 10442786
    Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: October 15, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Rino Antonio Bit, John Alexander Brown, Philip G. Humphreys, Katherine Louise Jones
  • Compounds
    Patent number: 10435391
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 8, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
  • Compounds
    Patent number: 10428078
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Benzoimidazole derivatives as PAD4 inhibitors
    Patent number: 10407407
    Abstract: Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: September 10, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Jessica Fanny Renaux, Robert John Sheppard, Ann Louise Walker, Christopher Roland Wellaway, David Matthew Wilson
  • ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS
    Publication number: 20190241573
    Abstract: The invention is directed to substituted isoquinoline derivatives and uses thereof. Specifically, the invention is directed to compounds according to Formula I and the use of compounds of Formula (I) in treating disease states: wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined herein.
    Type: Application
    Filed: July 18, 2017
    Publication date: August 8, 2019
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael AXTEN, Raghava Reddy KETHIRI, Rajendra KRISTAM, Chandregowda VENKATESHAPPA
  • Biaryl pyrazoles as NRF2 regulators
    Patent number: 10364256
    Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: July 30, 2019
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: James Callahan, Jeffrey K. Kerns, Peng Li, Tindy Li, Brent W. McCleland, Hong Nie, Joseph E. Pero, Thomas Glanmor Davies, Maria Grazia Carr, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, David Norton, Marinus Leendert Verdonk, Alison Jo-Anne Woolford, Hendrika Maria Gerarda Willems
  • Compounds
    Patent number: 10364266
    Abstract: A compound of Formula (I) wherein Y1, Y2, X1, X2, R1, R2, R3, R4, R5, R6, R8, and R9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: July 30, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jerry Adams, Yiqian Lian
  • Compounds for use in antibacterial applications
    Patent number: 10364254
    Abstract: The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: July 30, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Haifeng Cui, Alan Hennessy, Qi Jin, Timothy James Miles, Stephen Frederick Moss, Neil David Pearson